Ipsen continuously enhances its Business Ethics Program, backed by a robust infrastructure and governance system. By fostering a culture of ownership, accountability and mindful decision-making, we maintain a strong ethical foundation, as evidenced by positive employee survey results.

Ipsen is committed to ensuring a robust Opportunities and Risks Governance policy, with several strategic and operational committees actively working to identify, assess and address risks and opportunities.

In 2022, we implemented a comprehensive Supplier Risk Management process using a unified digital platform and engaging cross-functional experts to ensure potential suppliers meet our standards and Code of Conduct. This approach streamlines assessments and strengthens risk management throughout our organization.

At Ipsen, we care about protecting the personal data of all our stakeholders. We ensure that we only use personal data as necessary, that our use of that data is lawful and fair, that we keep data secure, and that we inform individuals about how we use their data. We manage privacy compliance at Ipsen through policies, procedures and training, and by fostering a strong culture of respect for privacy.

We are committed to fostering transparency and trust in all of our collaborations with healthcare professionals (HCPs) and healthcare organizations (HCOs). By openly disclosing information on transfers of value, clinical trials, scientific publications and interest representation activities, we ensure integrity and promote a strong ethical foundation across our interactions.

Ipsen actively collaborates with patient organizations to better understand and support patients’ needs. Emphasizing transparency, we publicly disclose financial and non-financial support provided to these organizations in adherence to the EFPIA Code.

Motivated by our strategic commitment to society as a whole, we seek out opportunities to make an impact. In 2022, in response to the war in Ukraine, Ipsen donated €1.5 million to two organizations helping those impacted: disaster-relief organization Tulipe and the International Red Cross in France.

Ipsen is committed to transparency in clinical studies, providing readily accessible information on clinical trials to patients, healthcare professionals and researchers. We publicly disclose protocol summaries and trial results, adhering to global industry standards, and share anonymized clinical study data with qualified researchers through the data-sharing platform, Vivli.

Ipsen does not have internal animal research facilities. Although Ipsen outsources its animal testing, it has put in place an Animal Welfare governance body ensuring the appropriate treatment of animals. We are signatories of Gircor’s “French Charter for Transparency on the Use of Animals for Scientific and Regulatory Purposes,” and actively pursue the 3Rs: reduction, refinement and replacement of animal experimentation

Our Early Access policy enables patients to obtain eligible Ipsen products that have not yet been approved by local health authorities, and thus otherwise unavailable for prescription.